NEUR100-0318: Seizure Management: Depolarization, Repolarization, and What we can do about it
The lectures for this course will be presented in an audio format using a webinar platform.
Enrollment is closed.
Presenters:
Anne Elizabeth Katherman, DVM, MS, DACVIM/Neurology
Dawn Boothe, Phd, DVM, DACVIM/Internal Medicine, DACVCP (Clinical Pharmacology)
Course Open: March 21-May 12, 2018
Real Time Sessions (RTS): Wednesdays, March 28, April 4, 11, 18, 25, and May 2, 2018; 9:00-11:00 pm ET (USA)
Course RTS Times in Your Area:
World Clock Converter
Level and Prerequisites:
This
intermediate course will be open to
veterinarians actively interested in seizure management.
VIN CE Course: Open to veterinarians.
This course is approved by RACE for veterinarians. (RACE 22-32184)
Course Information:
The primary purpose of this course is to provide an in depth understanding
of how various anticonvulsants work and how to use this information to
make decisions regarding which anticonvulsant to use for a given patient
and when to alter the dose or change the drug. The course will include a
discussion of seizure pathophysiology, general principles of seizure management,
drug monitoring and a discussion of the most commonly used anticonvulsants
in the canine and feline species. Case examples will be provided to illustrate
the principles of seizure management. Management of patients with cluster
seizures and status epilepticus will be included and alternatives for
anticonvulsants which are currently difficult to obtain will be discussed.
The course will also include an overview of the diagnostic workup for patients
with secondary seizures. Phenobarbital, Potassium Bromide, Zonisamide,
Keppra, Keppra XR, Gabapentin, Pregabalin, and Imepitoin will be discussed.
Week 1 (Real Time Session March 28, 2018):
Seizure Pathophysiology and Principles of Seizure Management
Presenter: Anne Elizabeth Katherman, DVM, MS, DACVIM/Neurology
Format: Audio (webinar)
Objectives: Upon completion of this session, the participant should be able to
- Identify the major excitatory and inhibitory neurotransmitters
- Identify the location of action for each anticonvulsant
- Explain how each anticonvulsant works
- List the important factors for judging anticonvulsant efficacy
- List the principles for adding and discontinuing anticonvulsants
Week 2 (Real Time Session April 4, 2018):
Introduction to Anticonvulsants and How They Work
Presenter: Dawn Boothe, PhD, DVM, DACVIM/Internal Medicine, DACVCP
Format: Audio (webinar)
Objectives: Upon completion of this session, the participant should be able to
- Given the half-life and dosing interval of a drug,
- determine if the drug will "fluctuate" or "accumulate",
- describe the best approach to monitoring;
- choose an appropriate response to modification of the dosing
regimen in a patient that has failed therapy;
- Implement a monitoring program based on an understanding of when and
why anticonvulsant monitoring can be helpful in making decisions
regarding addition or changes to anticonvulsant medication.
- Given the mechanism of action and the disposition of a drug, predict
- the relative risk of the drug in causing adverse events
and how disease or other patient factors might impact
the safety of that drug;
- the relative risk of drug interactions;
- predict the most appropriate anticonvulsant combination.
- Given a new "human" drug, identify the reasons why this drug should
or should not be used without scientific studies in the target species.
Week 3 (Real Time Session April 11, 2018):
Introduction to Anticonvulsants and How They Work - continued
Presenter: Dawn Boothe, PhD, DVM, DACVIM/Internal Medicine, DACVCP
Format: Audio (webinar)
Objectives: Upon completion of this session,
given a specific anticonvulsant drug, the participant should be able to
- List factors that might impact oral absorption and drug distribution;
- Predict whether the drug is likely to cause adverse events
and how to monitor and respond to these adverse events;
- Predict clinically relevant drug interactions and how to
prevent or respond to them;
- Establish an individualized monitoring program for that
drug for the patient;
- Describe the circumstances upon which the patient will be declared
refractory to monotherapy with that drug;
- Identify the most appropriate add-on anticonvulsant for the patient
and re-adjust the monitoring program for that patient accordingly;
Week 4 (Real Time Session April 18, 2018):
Uncomplicated Case Based Seizure
Presenters: Anne Elizabeth Katherman, DVM, MS, DACVIM/Neurology
Dawn Boothe, Phd, DVM, DACVIM/Internal Medicine, DACVCP
Format: Audio (webinar)
Objectives: Upon completion of this session, the participant should be able to
- Design and implement a safe and effective anti-epileptic treatment
course for the anti-epileptic na�ve patient. This includes:
- Identifying the major excitatory and inhibitory neurotransmitters;
- Choosing an appropriate anticonvulsant for the patient based
on presentation, patient factors (i.e., signalment) and client
considerations (including cost of drug and monitoring);
- Prescribe an initial dosing regimen;
- Design and implement a monitoring program for the patient,
based on clinical signs, clinical pathology and therapeutic drug monitoring;
- For therapeutic drug monitoring program with a focus on when, and how;
- Determine if and when a patient has failed the initial drug;
- Choose the most appropriate approach to failure;
- Identify key concepts to transmit to the client that will
proactively minimize emerging adverse events
(including therapeutic failure) in the patient;
Week 5 (Real Time Session April 25, 2018):
Complicated Case Based Seizure Management - continued
Presenters: Anne Elizabeth Katherman, DVM, MS, DACVIM/Neurology
Dawn Boothe, Phd, DVM, DACVIM/Internal Medicine, DACVCP
Format: Audio (webinar)
Objectives: Upon completion of this session, the participant should be able to
- Design and implement a safe and effective anti-epileptic treatment
course for the complicated anti-epileptic na�ve patient. This
includes all of the objectives in week 4, with an added emphasis of:
- Choosing the most appropriate add-on antiepileptic;
- Identifying the risk of adverse drug events and drug
interactions between combination antiepileptics;
- Designing therapeutic interventions that might be proactively
or after the fact implemented to reduce the risk of adverse events;
- Modify a monitoring program as needed for combination therapy;
- Determine when a patient has failed each stepwise modification
of an antiepileptic drug regimen;
- Identify non-traditional medications that might support
the refractory epileptic.
Week 6 (Real Time Session May 2, 2018):
Seizure Pathophysiology and Principles of Seizure Management
Presenter: Anne Elizabeth Katherman, DVM, MS, DACVIM/Neurology
Format: Audio (webinar)
Objectives: Upon completion of this session, the participant should be able to
- Understand the difference between cluster seizures and status epilepticus.
- Develop knowledge of the anticonvulsant options for specific
treatment of cluster seizures.
- Follow a logical approach to the treatment of status epilepticus.
- Know the signs of cerebral edema and the appropriate drugs for
attempting to counteract it.
- Recognize those patients that are most likely to have secondary
seizures based on signalment, history, physical, neurological and
laboratory examination results.
- List the general categories of diseases which can cause secondary seizures.
Successful completion (scoring 80% or better) on the end-of-course test is required
to earn a certificate of completion for the course.
To learn more about the requirements for earning a CE certificate, please refer to
Receiving Your CE Credit and Course Completion Certificate.
Course Materials: Course materials will be available
in the course library prior to each Real Time Session.
Required Textbook(s): There is no required textbook for this course.
About the Presenters:
Anne Elizabeth Katherman serves as a Veterinary Information
Network neurology consultant. In addition she develops continuing education
courses on neurology topics for VIN, does research for the VIN Drug Formulary
and is the associate editor for the neurology chapters in the VIN online
textbook Associate. Dr. Katherman did her residency training at Purdue
and Auburn Universities. Dr. Katherman lives in Hampton, Virginia.
Dr. Katherman previously owned a Neurology and Neurosurgery specialty practice
in Yorktown and Virginia Beach, Virginia, worked in both specialty and general
practices in Washington DC, Maryland and Virginia and was an assistant professor
at the Virginia Maryland Regional College of Veterinary Medicine. She has served
on various ACVIM committees and has been a reviewer for the JACVIM.
Dawn Boothe graduated from Texas A&M University (TAMU) in 1977
and 78 (BS), and a Doctor of Veterinary Medicine in 1980. After an internship
at Auburn University, she returned to TAMU to complete an MS in Physiology a
residency in small animal internal medicine (becoming board certified in 1985),
and a PhrMA Fellowship and PhD in Veterinary Clinical Pharmacology (1989).
She is among the first class of diplomates in the American College of Veterinary
Clinical Pharmacology (1991). In 1990, she joined TAMU in the Department of
Veterinary Physiology and Pharmacology, reaching Professor in 2003. She then
joined the departments of Anatomy, Physiology and Pharmacology and Clinical
Sciences at Auburn University's College of Veterinary Medicine as Professor.
She directs the Clinical Pharmacology Laboratory, serving over 4000 national
and international veterinary practices. She actively teaches in the 1st through
4th veterinary students, and has mentored over 31 graduate students or Clinical
Pharmacology Residents. Dr. Boothe has received over $1.7M research funding as
principle investigator, has authored or coauthored over 125 peer-reviewed scientific
publications, 2 text books and over 60 book chapters. Major awards include a
University Achievement Award in Teaching at Texas A&M University, the Jack Mara
Scientific Achievement Award for Scientific Achievement (national), and at AU,
graduate student mentor awards (University and College level) and the Zoetis
Award for Excellence in Research. She most recently was recognized by Auburn
University with an Alumni Professorship.
Total CE Credit: 12
Tuition: Member $276 ($248 early bird special if enrolled by March 7, 2018)
Non-Member $413 ($372 early bird special if enrolled by March 7, 2018)
Prices are listed in US dollars.
*To ensure participants are ready and prepared for classes,
enrollment will close on March 28, 2018 at 5 pm ET (USA)
or when the maximum number of participants is reached.
*For more information on how online CE works, see the
Participant Resource Center.
To Enroll:
Enrollment is closed.
- Enrollment qualifications: VIN CE courses are open to
VIN member and non-member veterinarians. Veterinarians enrolling in a VSPN CE course
must be a VIN member. Veterinary support staff must be a VSPN member to enroll in a
VSPN CE or a VIN CE course open to VSPN member enrollment.
- Each enrollee must be able to receive emails from @vspn.org
and @vin.com addresses. Email is our major form of communication with participants;
personal emails are highly recommended rather than clinic/hospital email addresses.
- Each person is individually responsible for his/her own registration.
To ensure that all information received is secure and correct, please do not enroll
for a course on behalf of another individual.
- For further assistance call 800-846-0028 ext. 797 or email
CEonVIN@vin.com.
Please include the course title, your full name, and contact information in your correspondence.
"This program (22-32184) is approved by the AAVSB RACE to offer a
total of 12 CE Credits, with a maximum of 12 CE Credits being available to any individual
veterinarian.
This RACE approval is for the subject matter categories of:
Scientific,
using the delivery method of Interactive-Distance: (Web-based, Teleconference or Audio-Conference).
This approval is valid in jurisdictions which recognize AAVSB RACE; however, participants are
responsible for ascertaining each board's CE requirements."
Course withdrawal and refund policy: A complete refund of the paid course price will be
issued when your withdrawal request is received prior to the listed start date of the course.
If you wish to withdraw after the start date please contact the VIN office 800-846-0028 ext. 797
to discuss eligibility for a pro-rated refund.
*For more information on VIN's upcoming CE courses, check the
VIN Course Catalog.
Katherine James, DVM, PhD, DACVIM (SAIM)
VIN Education Director
VIN CE Services:
CEonVIN@vin.com
800-846-0028 or 530-756-4881; ext. 797
or direct line to VIN/VSPN from the United Kingdom: 01 45 222 6154
or direct line to VIN/VSPN from Australia: 02 6145 2357
800.700.4636 | CEonVIN@vin.com | 530.756.4881 | Fax: 530.756.6035
777 West Covell Blvd, Davis, CA 95616
Copyright 2002, Veterinary Information Network, Inc.
|
